Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | MGAM | O43451 | 1/20 | 0.54 |
| ▸ | SI | P14410 | 1/20 | 0.54 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 5/20 | 0.40 |
| ▸ | PPARD | Q03181 | 5/20 | 0.40 |
| ▸ | PPARA | Q07869 | 5/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TLR2 | O60603 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1223746 | 0.88 | GAA (0.58) | GAAMGAMSIMGAM2TSHR | |
| SCHEMBL11246615 | 0.88 | GAA (0.58) | GAAMGAMSIMGAM2TSHR | |
| SCHEMBL6303692 | 0.86 | GAA (0.52) | GAAMGAMSIMGAM2TSHR | |
| SCHEMBL4476235 | 0.85 | GAA (0.61) | GAAMGAMSIMGAM2TSHR | |
| SCHEMBL6303688 | 0.85 | GAA (0.61) | GAAMGAMSIMGAM2TSHR | |
| SCHEMBL21794094 | 0.85 | TSHR (0.48) | TSHRKMT2AMAPTSLC22A6AKR1B1 | |
| SCHEMBL11226826 | 0.84 | CYP1A2 (0.53) | GAAMGAMSIMGAM2TSHR | |
| SCHEMBL17690729 | 0.84 | GAA (0.54) | GAAMGAMSIMGAM2TSHR | |
| SCHEMBL11599405 | 0.84 | GAA (0.54) | GAAMGAMSIMGAM2TSHR | |
| SCHEMBL6138808 | 0.83 | GAA (0.58) | GAAMGAMSIMGAM2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108037200-B | Quality detection method of kidney nourishing and tranquilizing pills | 广东沙溪制药有限公司 | 2020-05-12 | — | — | CN | claimed |
| CN-108037200-A | Quality detection method of kidney nourishing and tranquilizing pills | 广东益和堂制药有限公司 | 2018-05-15 | — | — | CN | claimed |
| CN-1876039-B | Detection method of pharmaceutical composition for treating upper respiratory tract infection | GUIYANG YUNYAN XICHUANG PHARMACEUTICAL DEV CO LTD | 2010-11-17 | — | — | CN | claimed |
| CN-1876039-A | Pharmaceutical composition for treating upper respiratory tract infection, its preparation process and quality control method | GUIYANG YUNYAN XICHUANG PHARM (CN) | 2006-12-13 | — | — | CN | claimed |
| EP-4748438-A2 | ENTERICALLY DELIVERED BITTER OLIGOPEPTIDES FOR THE TREATMENT FOR TYPE 2 DIABETES | Cedars-Sinai Medical Center (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260137751-A1 | ENTERICALLY DELIVERED BITTER OLIGOPEPTIDES FOR THE TREATMENT FOR TYPE 2 DIABETES | CEDARS-SINAI MEDICAL CENTER (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4194001-B1 | ENTERICALLY DELIVERED BITTER OLIGOPEPTIDES FOR THE TREATMENT OF TYPE 2 DIABETES AND OBESITY | CEDARS SINAI MEDICAL CENTER (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12551526-B2 | Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes | CEDARS-SINAI MEDICAL CENTER (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4194001-A1 | ENTERICALLY DELIVERED BITTER OLIGOPEPTIDES FOR THE TREATMENT FOR TYPE 2 DIABETES AND OBESITY | Cedars-Sinai Medical Center (US) | 2023-06-14 | — | — | EP | disclosed |
| CN-115963219-A | Method for detecting quality of goat milk leaf medicinal material | 贵州百灵企业集团制药股份有限公司 | 2023-04-14 | — | — | CN | disclosed |
| EP-3285795-B1 | ENTERICALLY DELIVERED BITTER OLIGOPEPTIDES FOR THE TREATMENT FOR TYPE 2 DIABETES AND OBESITY | CEDARS SINAI MEDICAL CENTER (US) | 2022-11-16 | — | — | EP | disclosed |
| CN-114366802-A | Enterally delivered bitter oligopeptides for the treatment of type 2 diabetes | 西达-赛奈医疗中心 | 2022-04-19 | — | — | CN | disclosed |
| CN-1853674-B | Detection method of Xingdan injection | GUIYANG YUNYAN XICHUANG PHARMACEUTICAL DEV CO LTD | 2010-04-14 | — | — | CN | disclosed |
| CN-101156893-A | Mass control method of apricot red injection | GUIYANG YUNYAN XICHUANG PHARM (CN) | 2008-04-09 | — | — | CN | disclosed |
| CN-1939392-A | Quality control of Chinese medicine compound preparation | QIYUANYIDE DRUG INST BEIJING (CN) | 2007-04-04 | — | — | CN | disclosed |
| CN-1939393-A | Quality control of Chinese-medicine compound preparation | QIYUANYIDE DRUG INST BEIJING (CN) | 2007-04-04 | — | — | CN | disclosed |
| CN-1876039-A | Pharmaceutical composition for treating upper respiratory tract infection, its preparation process and quality control method | GUIYANG YUNYAN XICHUANG PHARM (CN) | 2006-12-13 | — | — | CN | disclosed |
| CN-1853674-A | Quality Control Method of Xingdan Injection | YUNYANXICHUANG DRUG SCIENCE AN (CN) | 2006-11-01 | — | — | CN | disclosed |
| CN-1751718-A | Traditional Chinese medicine composition, prepn. method and quality control method therefor | CHEN RAN (CN) | 2006-03-29 | — | — | CN | disclosed |
| US-6316605-B1 | FOR USE IN RECORDING MATERIALS FOR THERMAL TRANSFER RECORDING, INK JET RECORDING | FUJI PHOTO FILM CO., LTD. (JP) | 2001-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137751-A1 | ENTERICALLY DELIVERED BITTER OLIGOPEPTIDES FOR THE TREATMENT FOR TYPE 2 DIABETES | GLP1R, GIPR, NPY2R | GAA 1775/4885MGAM 1504/4885SI 123/4885 |
| US-12551526-B2 | Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes | GLP1R, GIPR, NPY2R | GAA 2147/4885MGAM 1362/4885SI 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.